Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin.
OBJECTIVE
To investigate the relationship between low-dose aspirin-induced small bowel mucosal damage and blood flow, and the effect of rebamipide.


METHODS
Ten healthy volunteers were enrolled in this study. The subjects were divided into two groups: a placebo group given low-dose aspirin plus placebo and a rebamipide group given low-dose aspirin plus rebamipide for a period of 14 d. Capsule endoscopy and contrast-enhanced ultrasonography were performed before and after administration of drugs. Areas under the curves and peak value of time-intensity curve were calculated.


RESULTS
Absolute differences in areas under the curves were -1102.5 (95% CI: -1980.3 to -224.7, P = 0.0194) in the placebo group and -152.7 (95% CI: -1604.2 to 641.6, P = 0.8172) in the rebamipide group. Peak values of time intensity curves were -148.0 (95% CI: -269.4 to -26.2, P = 0.0225) in the placebo group and 28.3 (95% CI: -269.0 to 325.6, P = 0.8343) in the rebamipide group. Capsule endoscopy showed mucosal breaks only in the placebo group.


CONCLUSIONS
Short-term administration of low-dose aspirin is associated with small bowel injuries and blood flow.
Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Sapporo 060-8648, Japan.
Urara
U
Nishida
Mototsugu
M
Kato
Mutsumi
M
Nishida
Go
G
Kamada
Takeshi
T
Yoshida
Shouko
S
Ono
Yuichi
Y
Shimizu
Masahiro
M
Asaka
D000328:Adult; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D019540:Area Under Curve; D001241:Aspirin / Q000008:administration & dosage*; D001783:Blood Flow Velocity; D003287:Contrast Media / Q000494:pharmacology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004724:Endoscopy / Q000379:methods; D006801:Humans; D007421:Intestine, Small / Q000098:blood supply* / Q000187:drug effects*; D008297:Male; D010919:Placebos; D015363:Quinolones / Q000008:administration & dosage; D016896:Treatment Outcome; D014463:Ultrasonography / Q000379:methods
D000897:Anti-Ulcer Agents; D003287:Contrast Media; D010919:Placebos; D015363:Quinolones; C052785:rebamipide; D000409:Alanine; D001241:Aspirin
J Gastroenterol. 2008;43(4):270-6
18458842
Clin Gastroenterol Hepatol. 2009 May;7(5):524-9
19249402
Dig Dis Sci. 2007 Aug;52(8):1776-82
17410467
Aliment Pharmacol Ther. 2007 May 15;25(10):1211-22
17451567
Digestion. 2009;79(1):44-51
19246922
Rheumatology (Oxford). 1999 May;38 Suppl 1:24-32
10369403
Scand J Gastroenterol. 2007 Apr;42(4):513-8
17454863
Scand J Gastroenterol. 2007 Sep;42(9):1040-4
17710668
Scand J Gastroenterol. 2010 Mar;45(3):292-8
19968611
Jpn J Pharmacol. 1989 Apr;49(4):441-8
2542684
Ultrasound Med Biol. 2009 Feb;35(2):175-85
18845377
Dig Dis Sci. 1995 Nov;40(11):2469-72
7587834
Gastrointest Endosc. 2009 Jun;69(7):1339-46
19243767
Clin Gastroenterol Hepatol. 2005 Jan;3(1):55-9
15645405